Regardless of the type of therapy, the prognosis has been a dismal
reported median overall survival of 12 - 16 months and high rate of relapse within 1 year [1 - 3].
Not exact matches
Now, at 5.3 years
median follow up, the impact on
overall survival is
reported and represents a 28 % reduction of the relative risk of death (hazard ratio 0.72, p = 0.001).
Retrospective case
reports suggest that adults may benefit from consolidation with allogeneic HSCT during their first CR following chemotherapy with one study observing a
median overall survival of 38.5 months [5].
The
median overall survival of patients in the Phase 1 resection injection study, where Toca 511 was injected into the wall of the resection cavity after removal of the tumor, exceeds historical controls across a variety of previously
reported clinical trials.